Status:
RECRUITING
Hybrid Florbetaben PET/MRI for Imaging of Cardiac Amyloidosis
Lead Sponsor:
University Hospital, Essen
Conditions:
Cardiac Amyloidosis
Eligibility:
All Genders
40+ years
Brief Summary
Exploration of prognostic parameters in 18F-Florbetaben PET/MRI in patients with cardiac amyloidosis. The clinical endpoints are defined as occurence of major adverse cardiac events (MACE) in amyloido...
Detailed Description
The aim of the study is to investigate the value of hybdrid imaging using 18F-Florbetaben PET/MRI for detecting prognostically relevant disease markers in patients with cardiac amyloidosis. The clinic...
Eligibility Criteria
Inclusion
- Age \> 40 years
- proven Amyloidosis (ATTR or AL)
- Women: negative pregnancy test less than weeks prior imaging.
Exclusion
- Patients receiving amyloidosis-specific treatment prior study inclusion.
- Patients participating in other clinical trails for treatment of Amyloidosis.
- Pregnancy
- Contraindiactions for MRI (eGFR\<30ml/min/1.73m2; gadolinium allergy; metallic implants or device not suited for 3T MRI).
- inability of consent
- Refusal of consent
Key Trial Info
Start Date :
December 9 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT07154381
Start Date
December 9 2019
End Date
December 1 2025
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nuclear medicine, University Hospital Essen
Essen, North Rhine-Westphalia, Germany, 45147